{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:57:01Z","timestamp":1784901421530,"version":"3.55.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.2217\/imt-2022-0191","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T08:08:30Z","timestamp":1673251710000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Update on Immunotherapy in the Management of Gallbladder Cancer"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6761-7636","authenticated-orcid":false,"given":"Joseph","family":"Kassab","sequence":"first","affiliation":[{"name":"Department of Hematology &amp; Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Saba","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-6415","authenticated-orcid":false,"given":"Georges","family":"Gebrael","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Kais","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-6526","authenticated-orcid":false,"given":"Rebecca","family":"Kassab","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig R","family":"Kourie","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951115)76:10<1747::AID-CNCR2820761011>3.0.CO;2-L"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.51.6.349"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01658723"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21141"},{"issue":"8","key":"e_1_3_3_7_1","first-page":"415","article-title":"Primary carcinoma of the gallbladder: operative experience during a 16 year period","volume":"159","author":"Oertli D","year":"1993","unstructured":"Oertli D , HerzogU , TondelliP. Primary carcinoma of the gallbladder: operative experience during a 16 year period. Eur. J. Surg. Acta Chir.159(8), 415\u2013420 (1993).","journal-title":"Eur. J. Surg. Acta Chir."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01039"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200010000-00011"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12444"},{"issue":"9","key":"e_1_3_3_11_1","first-page":"981","article-title":"Gallbladder carcinoma in the era of laparoscopic cholecystectomy","volume":"131","author":"Yamaguchi K","year":"1996","unstructured":"Yamaguchi K , ChijiiwaK , IchimiyaHet al. Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch. Surg. Chic. Ill 1960.131(9), 981\u2013984; discussion 985 (1996).","journal-title":"Arch. Surg. Chic. Ill 1960."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2009.00108.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11618"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4006"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.225"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02178"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2219"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.08.020"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.10.004"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz058"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:DRUG.0000011797.09549.53"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20368"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00486-1"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903033"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2679"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.COC.0000018037.59196.67"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9885-2"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.378"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"e_1_3_3_32_1","unstructured":"US FDA\n. FDA approves durvalumab for locally advanced or metastatic biliary tract cancer (2022). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_3_35_1","unstructured":"US FDA\n. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication (2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2016.10.04"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2814"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168996"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0432"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-013-2286-2"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9583-z"},{"key":"e_1_3_3_43_1","unstructured":"Merck Sharp DohmeLLC. A phase 3 randomized double blind study of pembrolizumab plus gemcitabine\/cisplatin versus placebo plus gemcitabine\/cisplatin as first-line therapy in participants with advanced and\/or unresectable biliary tract carcinoma. (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04003636"},{"key":"e_1_3_3_44_1","unstructured":"European Organisation for Research and Treatment of Cancer\n. Open-label first line single-arm phase II study of cisgem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03260712"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1426519"},{"key":"e_1_3_3_46_1","unstructured":"EMD Serono Research & Development Institute Inc\n. A phase II\/III multicenter randomized placebo-controlled study of gemcitabine plus cisplatin with or without bintrafusp alfa (M7824) as first-line treatment of biliary tract. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04066491"},{"key":"e_1_3_3_47_1","unstructured":"AIO-Studien-gGmbH\n. A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-na\u00efve patients with cholangio- and gallbladder carcinoma (IMMUCHEC) (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03473574"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001240"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33751"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e16170"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4100"},{"key":"e_1_3_3_52_1","unstructured":"Kuang M\n. Adjuvant immunotherapy combined with chemoradiation for patients with high-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer: a phase II multicenter randomized controlled trial (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333927"},{"key":"e_1_3_3_53_1","unstructured":"AIO-Studien-gGmbH\n. A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-na\u00efve patients with cholangio- and gallbladder carcinoma (IMMUCHEC) (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03473574"},{"key":"e_1_3_3_54_1","unstructured":"Liu T\n. A single-arm single-center prospective clinical study of the efficacy and safety of chemotherapy combined with toripalimab in the treatment of advanced biliary tract cancer (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03796429"},{"key":"e_1_3_3_55_1","unstructured":"Kuang M\n. Adjuvant immunotherapy combined with chemoradiation for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: a phase II multicenter randomized controlled trial (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333927"},{"key":"e_1_3_3_56_1","unstructured":"Institut f\u00fcr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest\n. A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05239169"},{"key":"e_1_3_3_57_1","unstructured":"Yoo C\n. Randomized phase 2 study of preoperative gemcitabine plus cisplatin with or without durvalumab (MEDI4736) followed by postoperative durvalumab (MEDI4736) in patients with localized biliary tract cancer (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308174"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2022-0191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:37:51Z","timestamp":1715953071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2022-0191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2217\/imt-2022-0191"],"URL":"https:\/\/doi.org\/10.2217\/imt-2022-0191","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}